[breadcrumb_custom]

Revance Therapeutics Inc (NASDAQ:RVNC): Buy, Sell Or Hold At $5.42?

In last trading session, Revance Therapeutics Inc (NASDAQ:RVNC) saw 1.67 million shares changing hands with its beta currently measuring 1.00. Company’s recent per share price level of $5.42 trading at $0.04 or 0.74% at ring of the bell on the day assigns it a market valuation of $475.93M. That closing price of RVNC’s stock is at a discount of -600.74% from its 52-week high price of $37.98 and is indicating a premium of 7.75% from its 52-week low price of $5.00. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.55 million shares which gives us an average trading volume of 1.63 million if we extend that period to 3-months.

Revance Therapeutics Inc (NASDAQ:RVNC) trade information

Upright in the green during last session for gaining 0.74%, in the last five days RVNC remained trading in the green while hitting it’s week-highest on Tuesday, 02/06/24 when the stock touched $5.42 price level, adding 8.91% to its value on the day. Revance Therapeutics Inc’s shares saw a change of -38.34% in year-to-date performance and have moved 5.24% in past 5-day. Revance Therapeutics Inc (NASDAQ:RVNC) showed a performance of -22.90% in past 30-days. Number of shares sold short was 14.81 million shares which calculate 9.6 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Revance Therapeutics Inc (RVNC) estimates and forecasts

Statistics highlight that Revance Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -73.19% of value to its shares in past 6 months, showing an annual growth rate of 19.18% while that of industry is 15.30. Apart from that, the company came raising its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -4.10% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 17.25% while estimates for its earnings growth in next 5 years are of 11.60%.

RVNC Dividends

Revance Therapeutics Inc is more likely to be releasing its next quarterly report between February 26 and March 12 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Revance Therapeutics Inc (NASDAQ:RVNC)’s Major holders

Insiders are in possession of 9.50% of company’s total shares while institution are holding 94.83 percent of that, with stock having share float percentage of 104.79%. Investors also watch the number of corporate investors in a company very closely, which is 94.83% institutions for Revance Therapeutics Inc that are currently holding shares of the company. Capital World Investors is the top institutional holder at RVNC for having 9.57 million shares of worth $242.34 million. And as of Jun 29, 2023, it was holding 10.89% of the company’s outstanding shares.

The second largest institutional holder is Blackrock Inc., which was holding about 6.53 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 7.42% of outstanding shares, having a total worth of $165.19 million.

On the other hand, Smallcap World Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 6.38 million shares of worth $161.44 million or 7.25% of the total outstanding shares. The later fund manager was in possession of 2.56 million shares on Jun 29, 2023, making its stake of worth around $64.77 million in the company or a holder of 2.91% of company’s stock.

On Key

Related Posts